发布求助
文献互助 智能选刊 最新文献

Idrugs最新文献

筛选
英文 中文
The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 2. 免疫治疗学和疫苗峰会- CHI的第五届年会-新型疫苗:佐剂和递送系统:第2部分。
Idrugs Pub Date : 2010-10-01
Susan D Jones
{"title":"The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 2.","authors":"Susan D Jones","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Fifth Annual Immunotherapeutics and Vaccine Summit (ImVacS), held in Boston, included topics covering new developments in the field of adjuvants and delivery systems for vaccines. This conference report highlights selected presentations on vaccines for infectious diseases, the use of adenovirus 5 (Ad5) for oral vaccination, modes of delivery for vaccines, and the strategy of DNA vaccination.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 10","pages":"692-4"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29313247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders. Preladenant，一种新型腺苷a (2A)受体拮抗剂，用于治疗帕金森病和其他疾病。
Idrugs Pub Date : 2010-10-01
John D Salamone
{"title":"Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.","authors":"John D Salamone","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Adenosine A(2A) receptor antagonists exert antiparkinsonian effects in animal models and several drugs in this class are currently being assessed in clinical trials. Preladenant (SCH-420814) is an adenosine A(2A) receptor antagonist with a high affinity and very high selectivity for adenosine A(2A) receptors, which is being developed by Merck & Co Inc (following its acquisition of Schering-Plough Corp) for the potential treatment of Parkinson's disease. Preclinical studies in rodent and primate models of parkinsonism demonstrated that preladenant can reverse the motor impairments induced by dopamine depletion or antagonism. Phase I and II clinical trials indicated that preladenant was well tolerated. Moreover, preladenant met its major endpoints by reducing OFF time and increasing ON time in l-DOPA-treated patients with Parkinson's disease, without worsening dyskinesias. Therefore, preladenant may have considerable utility for the treatment of Parkinson's disease, as well as the parkinsonian side effects of dopamine D2 receptor antagonists. As research has suggested that adenosine A(2A) receptor antagonists are active in animal models of effort-based decision making, it is possible that preladenant could also be useful for treating energy-related symptoms, such as fatigue, psychomotor retardation and anergia in patients with parkinsonism or depression. At the time of publication, phase III clinical trials were recruiting patients with Parkinson's disease.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 10","pages":"723-31"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29313253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1. 美国化学会。第240次全国会议。预防和对抗疾病的化学:第1部分。
Idrugs Pub Date : 2010-10-01
Jessica Burt
{"title":"American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.","authors":"Jessica Burt","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 240th National Meeting of the American Chemical Society, held in Boston, included topics covering new therapeutic research. This conference report highlights selected presentations on negative allosteric modulators of metabotropic glutamate receptor 5 (mGluR5) for the treatment of Parkinson's disease, BACE1 inhibitors and γ-secretase inhibitors for the prevention or treatment of Alzheimer's disease, opioid modulators for the treatment of reward disorders, SGLT2 inhibitors for the treatment of diabetes, backup compounds to the DPP-4 inhibitor sitagliptin (Januvia) for type 2 diabetes, and MCH R1 inhibitors for the treatment of obesity. Investigational drugs discussed include SCH-1359113 and SCH-1682496 (both Merck & Co), NGP-555 (NeuroGenetic Pharmaceuticals), ALKS-33 (Alkermes), dapagliflozin (Bristol-Myers Squibb/AstraZeneca) and GSK-882380 (GlaxoSmithKline).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 10","pages":"669-72"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29311681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 1. 免疫治疗学和疫苗峰会- CHI的第五届年会-新型疫苗:佐剂和递送系统:第1部分。
Idrugs Pub Date : 2010-10-01
Susan Dana Jones
{"title":"The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 1.","authors":"Susan Dana Jones","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Fifth Annual Immunotherapeutics and Vaccine Summit (ImVacS), held in Boston, included topics covering new developments in the field of adjuvants and delivery systems for vaccines. This conference report highlights selected presentations on improving vaccine quality and persistence through adjuvants, the development of AS04-adjuvanted Cervarix, and research on new adjuvants. Adjuvants discussed include thymalfasin, nutritive immune-enhancing delivery system (NIDS), W805EC, MIMOPATH and ISCOMATRIX; the use of lasers as adjuvants is also highlighted.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 10","pages":"689-91"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29311687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ubiquitin Drug Discovery and Diagnostics Conference - targeting E3 ligases. 泛素药物发现和诊断会议-靶向E3连接。
Idrugs Pub Date : 2010-10-01
Jennifer A Johnston
{"title":"Ubiquitin Drug Discovery and Diagnostics Conference - targeting E3 ligases.","authors":"Jennifer A Johnston","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Ubiquitin Drug Discovery and Diagnostics Conference, held in Philadelphia, included topics covering the role of E3 ligases in disease. This conference report highlights selected presentations on E3-E2 ligase interactions, the SCF cyclin F ubiquitin ligase complex, and targeting HectH9 and KF-1 E3 ligases. Pharmaceutical research discussed includes E3 programs from Progenra and efforts to modulate the Parkin ligase at Elan Pharmaceuticals.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 10","pages":"695-7"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29313248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Cannabinoid Research Society - 20th annual symposium. 国际大麻素研究学会第二十届年会。
Idrugs Pub Date : 2010-10-01
David P Finn
{"title":"International Cannabinoid Research Society - 20th annual symposium.","authors":"David P Finn","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 20th Annual International Cannabinoid Research Society (ICRS) symposium, held in Lund, Sweden, included topics covering new therapeutic developments in the field of cannabinoids. This conference report highlights selected presentations on drug design and discovery, Δ⁹-tetrahydrocannabivarin, inhaled dronabinol, the presence of cannabinoid receptor 2 in brain neurons, and the role of the endocannabinoid 2-arachidonoylglycerol in the brain.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 10","pages":"677-9"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29311683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ABCs of cancer stem cell drug resistance. 癌症干细胞耐药的基本原理。
Idrugs Pub Date : 2010-09-01
Aaron Elliott, Aaron Elliot, Jerry Adams, Muhammad Al-Hajj
{"title":"The ABCs of cancer stem cell drug resistance.","authors":"Aaron Elliott,&nbsp;Aaron Elliot,&nbsp;Jerry Adams,&nbsp;Muhammad Al-Hajj","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Chemotherapy is generally effective as a non-targeted therapy in killing the majority of cells in a tumor; however, a small population of residual cells that are intrinsically resistant to such agents persist after chemotherapy, ultimately resulting in patient relapse. There is evidence that these cells within resistant tumors are cancer stem cells. A common mechanism of multidrug resistance used by residual tumor cells involves the expression of the ATP-binding cassette (ABC) transporters. Understanding the anticancer drug transport properties of these transporters, as well as their physiological functions, in addition to improved efforts to discover and characterize selective inhibitors, will lead to more effective therapeutics for oncology.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"632-5"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29267468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
European Neuroscience--Seventh Biennial FENS Forum. 第七届欧洲神经科学论坛。
Idrugs Pub Date : 2010-09-01
Anthony J Hannan
{"title":"European Neuroscience--Seventh Biennial FENS Forum.","authors":"Anthony J Hannan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The European Neuroscience--Seventh Biennial FENS Forum, held in Amsterdam, included topics covering new therapeutic developments in the field of neuroscience. This conference report highlights selected presentations on sodium channel inhibitors, ionotropic glutamate receptor antagonists, serotonin receptor modulators, and novel therapies for depression, pain and stroke. Investigational drugs discussed include ST-1936 (Sigma-Tau Industrie Farmaceutiche Riunite SpA), LY-392098 (Eli Lilly & Co) and Lu-AA21004 (H Lundbeck A/S/Takeda Pharmaceutical Co Ltd).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"607-9"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29269509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AIDS 2010--XVIII International AIDS Conference. 艾滋病2010——第十八届国际艾滋病大会。
Idrugs Pub Date : 2010-09-01
Belete A Desimmie
{"title":"AIDS 2010--XVIII International AIDS Conference.","authors":"Belete A Desimmie","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The AIDS 2010-XVIII International AIDS Conference, held in Vienna, included topics covering new therapeutic developments in the field of HIV therapy. This conference report highlights selected presentations on novel HIV entry inhibitors, reverse transcriptase inhibitors, integrase inhibitors and clinical trial data for an NRTI-based, antiviral, hyperactivation-limiting therapeutic. Investigational drugs discussed include GSK-1349572 (Viiv Healthcare/Shionogi & Co Ltd) and VS-411 (ViroStatics).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"622-5"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29269513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. Iniparib是一种PARP1抑制剂，可用于治疗包括三阴性乳腺癌在内的癌症。
Idrugs Pub Date : 2010-09-01
Hongyang Liang, Antoinette R Tan
{"title":"Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.","authors":"Hongyang Liang,&nbsp;Antoinette R Tan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>PARP inhibitors are a promising, novel class of anticancer agents. Iniparib (BSI-201) is an intravenously administered PARP1 inhibitor under development by BiPar Sciences Inc, a subsidiary of sanofi-aventis, under license from Octamer Inc, for the potential treatment of cancer. Iniparib, either alone or in combination with chemotherapy, had significant antitumor activity in preclinical studies in vitro and in vivo. Phase I clinical trials in patients with solid tumors demonstrated that treatment with iniparib was associated with minimal toxicity. Encouraging results were observed in a randomized phase II clinical trial, which demonstrated that the addition of iniparib to gemcitabine and carboplatin led to an improvement in clinical benefit rate, progression-free survival and overall survival in patients with metastatic triple-negative breast cancer (TNBC) compared with gemcitabine and carboplatin alone. A phase III clinical trial to test the survival benefit of iniparib in combination with gemcitabine and carboplatin in metastatic TNBC has completed accrual. Another phase III clinical trial will evaluate the overall survival of patients with newly diagnosed stage IV squamous NSCLC treated with gemcitabine and carboplatin with or without iniparib. Several phase II clinical trials of iniparib as a single agent or in combination with chemotherapy are ongoing in other tumor types, such as ovarian and uterine cancer, NSCLC and glioblastoma. These trials will clarify the role of iniparib in the treatment of cancer, including TNBC.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"646-56"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29267470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信